| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5424286 | ASTRAZENECA AB | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
Dec, 2016
(7 years ago) | |
| US6858576 | ASTRAZENECA AB | Methods for regulating gastrointestinal motility |
Jan, 2017
(7 years ago) | |
| US7521423 | ASTRAZENECA AB | Exendin pharmaceutical compositions |
Oct, 2017
(6 years ago) | |
| US7297761 | ASTRAZENECA AB | Pharmaceutical compositions containing exendins |
Oct, 2017
(6 years ago) | |
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| US6902744 | ASTRAZENECA AB | Exendin agonist formulations and methods of administration thereof |
Jan, 2020
(4 years ago) | |
Byetta is owned by Astrazeneca Ab.
Byetta contains Exenatide Synthetic.
Byetta has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Byetta are:
- US5424286
- US6858576
- US7521423
- US7297761
- US7741269
- US6956026
- US6872700
- US6902744
Byetta was authorised for market use on 28 April, 2005.
Byetta is available in injectable;subcutaneous dosage forms.
Byetta can be used as reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4, use of exenatide may result in reduction in body weight, treating type 2 diabetes mellitus with exenatide by stimulating insulin release, reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4, lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
The generics of Byetta are possible to be released after 04 November, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-232) | Nov 04, 2024 |
| M(M-148) | Nov 24, 2017 |
| M(M-113) | Oct 19, 2014 |
| M(M-111) | Oct 19, 2014 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 28 April, 2005
Treatment: Treating type 2 diabetes mellitus with exenatide by stimulating insulin release; Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4; Use of exenatide...
Dosage: INJECTABLE;SUBCUTANEOUS
BYETTA family patents
